MetaCap

Lexicon Pharmaceuticals Inc. (LXRX)

NASDAQ: LXRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.53-0.14 (-8.38%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LXRX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$681.21M
EPS (TTM)
-$0.15
52-week range
1.10 – 2.68
Day range
1.47 – 1.70
Volume / Avg
4.20M / 2.56M
Beta
—

52-week range

$1.10$2.68

LXRX stock today

Shares of Lexicon Pharmaceuticals (LXRX) finished lower on Nov 20 at $1.53, a drop of 8.38% or $0.14 per share, versus the S&P 500's 3.70% decline. At this level, LXRX sits in the middle of its 52-week range of $1.10 to $2.68: 42.9% below the high, set on Jun 30, 2026 and 39.1% above the low. LXRX is up 33.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 14.2%.

Lexicon Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.15), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Lexicon Pharmaceuticals

Company profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Michael S. Exton Ph.D.
Headquarters
The Woodlands, TX
Employees
81

Financial highlights

Full financials

In fiscal 2025, Lexicon Pharmaceuticals generated $49.8 million in revenue, up 60.2% from fiscal 2024, its 3rd consecutive year of revenue growth. Lexicon Pharmaceuticals reported a net loss of $50.3 million, compared with a loss of $200.4 million a year earlier. Gross margin was 99.4% (up from 98.0%) and operating margin -98.2%.

Lexicon Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$49.80M$31.08M$1.20M$139.00K$298.00K
Growth+60.24%+2481.48%+766.19%-53.36%-98.76%
Net income$-50.34M$-200.40M$-177.12M$-101.94M$-87.76M
EPS (diluted)$-0.14$-0.63$-0.80$-0.62$-0.60

Analyst forecast

Forecast

Consensus (6 analysts)

buy

Avg. price target

$4.52+195.42%

  • Strong buy 1
  • Buy 3
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $1.69High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.03 vs $-0.06
Surprise
+50.00%

LXRX news

All LXRX news

Lexicon Pharmaceuticals peers

Health Care sector
LXRX peer companies
CompanyPrice% ChgMarket capCompare
APMDApnimed Inc.16.09-6.70%$669.84Mvs LXRX
NVCTNuvectis Pharma Inc.19.39-2.27%$666.80Mvs LXRX
SGMTSagimet Biosciences Inc. Series A9.08-5.61%$648.02Mvs LXRX
KURAKura Oncology Inc.6.91-5.99%$634.88Mvs LXRX
OBXObsidian Therapeutics Inc.12.00-1.23%$741.29Mvs LXRX
JANXJanux Therapeutics Inc.10.08-2.04%$616.73Mvs LXRX
ABUSArbutus Biopharma Corporation4.02-1.23%$616.24Mvs LXRX
OLMAOlema Oncology Inc.7.02-1.82%$615.00Mvs LXRX

Indexes, lists and sector

Lexicon Pharmaceuticals stock FAQ

What is Lexicon Pharmaceuticals's stock price today?

LXRX last traded at $1.53 as of Nov 20, 4:00 PM EST, down 8.38% on the day. Prices are delayed at least 15 minutes.

Does Lexicon Pharmaceuticals pay a dividend?

No. Lexicon Pharmaceuticals does not currently pay a regular cash dividend.

Who is Lexicon Pharmaceuticals's CEO?

Dr. Michael S. Exton Ph.D. is the chief executive officer of Lexicon Pharmaceuticals Inc., which has about 81 employees.

Has LXRX ever split its stock?

Yes. The most recent LXRX stock split was a 1-for-7 split on May 21, 2015.

What is the LXRX 52-week high?

The 52-week high for LXRX is $2.68 and the 52-week low is $1.10. The stock is currently 42.9% below its high.

Compare LXRX